Jew World Order

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016

Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals

In 2015, President Obama announced the Precision Medicine Initiative (PMI) in order to “usher in a new era of medicine that will harness data to support and advance research, technology and policies and to empower health care providers and patients … that builds on the work that was done in mapping out the human genome.”

A year ago, the Obama administration revealed PMI requires the creation of a “1 million-plus patient repository of genetic information spanning many diseases, giving researchers valuable insights to design the next generation of treatments for patients.”

Speaking at a summit on health and science , the president spoke about “spurring on a whole new set of understandings about how diseases operate, about how the human body, how cells operate, how areas like cancer show how each cancer may be unique, even if it’s in the same organ.”

PMI is described as “tailoring medicine to [individual], unique biological needs” and the matching of a diagnosis and “treatment strategy to each individual’s unique molecular makeup.”

At the time of the PMI launch, the president asked for $215 million to pay for a way to “revolutionize the way we approach health in this country and, ultimately, around the world.”

While medicine has historically developed out of the need for the “average” person, the “result of this one-size-fits-all-approach, treatments can be very successful for some patients but not for others.”

In a statement the White House conveyed: “This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles.”

Also known as “personalized medicine”, this new model of health care “involves the selection of diagnostic tests that have the potential to identify changes in each individual patient’s cancer cells. The use of that knowledge may help to prevent and treat cancer through the development of treatment strategies to target these specific molecular alterations. Ultimately, the goal of precision oncology is to improve patient outcomes.”

According to the White House FACT SHEET, the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) will be collaborating and sharing tax payer money:

• $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
• $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
• $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
• $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.

To combat cancer, the NCI will create “a national ‘cancer knowledge network’ will generate and share new knowledge to fuel scientific discovery and guide treatment decisions.”

The NIH “will launch a national, patient-powered research cohort of one million or more Americans who volunteer to participate in research. Participants will be involved in the design of the Initiative and will have the opportunity to contribute diverse sources of data—including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data.”

The HHS will be tasked with soliciting “input from patient groups, bioethicists, privacy, and civil liberties advocates, technologists, and other experts in order to identify and address any legal and technical issues related to the privacy and security of data in the context of precision medicine.”

The FDA “will develop a new approach for evaluating Next Generation Sequencing technologies — tests that rapidly sequence large segments of a person’s DNA, or even their entire genome … [to] facilitate the generation of knowledge about which genetic changes are important to patient care and foster innovation in genetic sequencing technology, while ensuring that the tests are accurate and reliable.”

In addition, the president is setting up a public-private partnership with “academic medical centers, researchers, foundations, privacy experts, medical ethicists, and medical product innovators to lay the foundation for this effort, including developing new approaches to patient participation and empowerment.”

Kathy Giusti, founder of the Multiple Myeloma Research Foundation (MMRF) commented : “For more than five years, we have worked with the world’s leaders in precision medicine from industry and academia to build a new research approach from the ground up, first sequencing the myeloma genome, and then designing and launching the largest long-term research study ever conducted in our disease.”

Giusti continued: “We now track the progress of more than 800 participants, looking for correlations between a patient’s genetic profile, disease progression, and response to therapy. We share the results in the public domain as soon as they are available, with an eye toward improving clinical care today, and pointing the way to the targeted therapies of tomorrow.”

Related Posts

By Susanne Posel – February 25, 2016

By Susanne Posel – February 24, 2016

By Susanne Posel – February 23, 2016

By Susanne Posel – February 19, 2016